Health and Healthcare
Why Voyager Therapeutics Shares Are Surging
Published:
Last Updated:
Voyager Therapeutics Inc. (NASDAQ: VYGR) shares saw a handy gain on Tuesday after the company announced that it received some feedback from the U.S. Food and Drug Administration (FDA) from its Type C meeting.
Based on the written response from the FDA, Voyager continues to plan to submit for review a biologics license application (BLA) for VY-AADC based on the nonclinical and clinical safety and efficacy data from the pivotal program, including plans to submit a BLA based on data from the Phase 2 trial alone, or if needed, from the randomized, placebo-controlled Phase 3 trial.
Additionally, Voyager announced positive interim results from a Phase 1 posterior trajectory trial that achieved enhanced coverage of the putamen, reduced surgical times and improvements in patients’ motor function at six months. As a result, Voyager has determined that the posterior approach will continue to serve as the preferred surgical route of administration and that the pivotal program will use a dose concentration of VY-AADC between those used in Cohorts 2 and 3 from the Phase 1b trial.
Robert Pietrusko, Pharm.D., senior vice president of regulatory affairs and quality assurance at Voyager, commented:
We are very pleased with feedback from the FDA regarding our pivotal program for VY-AADC that includes the potential to file a BLA based on the safety and efficacy results from the Phase 2 trial, or if needed, from the Phase 3 trial. With the recent RMAT designation for VY-AADC and written feedback from the FDA regarding our Type C meeting questions, we look forward to continuing to work closely with the agency to expedite the development of this potentially important treatment for patients with Parkinson’s disease.
Shares of Voyager were last seen up about 8% at $19.44, with a consensus analyst price target of $32.73 and a 52-week trading range of $8.10 to $31.91.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
